Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $30.27

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $30.2727.

Several equities research analysts have recently commented on BCAX shares. Citizens Jmp reissued a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Wells Fargo & Company raised their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Guggenheim started coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st.

Bicara Therapeutics Price Performance

BCAX opened at $27.02 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of -9.72 and a beta of -0.81. The stock’s 50 day simple moving average is $24.55 and its 200 day simple moving average is $20.89. Bicara Therapeutics has a 1-year low of $9.57 and a 1-year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Research analysts expect that Bicara Therapeutics will post -3.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Friday, July 10th. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,292,359.84. The trade was a 2.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 88,450 shares of company stock worth $2,366,675. 13.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics in the fourth quarter valued at $45,000. Larson Financial Group LLC grew its stake in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.